- Home
- CELZ vs PULM Comparison
CELZ vs PULM Comparison
Compare CELZ & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELZ | PULM |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.2M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CELZ | PULM |
|---|---|---|
| Price | $0.75 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 105.9K | 18.6K |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.08 | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | $6,000.00 | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.62 | $1.16 |
| 52 Week High | $6.25 | $4.98 |
Technical Indicators
Market Signals| Indicator | CELZ | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 50.46 |
| Support Level | $0.62 | $1.41 |
| Resistance Level | $0.93 | $1.82 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 22.61 | 51.09 |
Price Performance
Historical ComparisonAbout CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).